Manali Kamdar, MD, on Bringing Liso-Cel to Earlier Lines of Treatment

Commentary
Video

The associate professor of medicine at University of Colorado discussed data in the primary relapsed LBCL setting.

“Investigating liso-cel even earlier, besides just waiting for the patients to relapse, and then give it to them makes a lot of sense. But I feel it absolutely needs to be tested with scientific rigor within a clinical trial setting. There is some data that's emerging where we could bring liso-cel if interim PET scans are partial response or stable disease. And I think that may be the next opportunity to showcase the strength of liso-cel in terms of bringing it to earlier line settings.”

Lisocabtagene maraleucel (liso-cel) has continued to demonstrate deep responses in patients with primary refractory/relapsed (r/r) large B-cell lymphoma (LBCL) and superiority over standard of care. The therapy is approved under the name Breyanzi for patients with r/r LBCL based off of data from the phase 3 TRANSFORM (NCT03575351) and TRANSCEND trials (NCT02631044).

Updated, 3-year data from TRANSFORM were presented by Manali Kamdar, MD, associate professor of medicine – hematology, University of Colorado School of Medicine - Anschutz Medical Campus, and UCHealth Blood Disorders and Cell Therapies Center at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31 to June 4, in Chicago, Illinois. CGTLive® spoke with Kamdar to learn more about moving liso-cel and other chimeric antigen receptor (CAR) T-cell therapies to earlier lines of therapy.

Click here to view more coverage from the 2024 ASCO meeting.

REFERENCE
Kamdar MK, Solomon SR, Arnason J, et al. Lisocabtagenemaraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study. Presented at: 2024 (ASCO) Annual Meeting; May 31 - June 4; Chicago, Illinois. Abstract #7013
Recent Videos
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
© 2025 MJH Life Sciences

All rights reserved.